 (PKTEF) Stock, Quote.Headers.trade-ideas

Parkit Enterprise Inc is an investment real estate platform. It is focused on the acquisition, growth, and management of strategically located industrial properties across key markets in Canada, with a focus on the Greater Toronto Area (GTA), Ottawa, and Montreal, to complement its parking assets across the United States. The Company operates in two reportable business segments: Investment Properties which involves the acquisition and management of income producing industrial properties across key markets in Canada. Parking Assets which involves the acquisition and management of income producing parking facilities across the United States.

PARKIT ENTERPRISE INC ORD by Parkit Enterprise Inc.

Parkit Enterprise Inc

<a href="https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.">https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.</a>
&nbsp;
EMA has recommended extending the indication of the smallpox and mpox vaccine <a href="https://www.ema.europa.eu/node/65501">Imvanex</a> to adolescents from 12 to 17 years of age.
Imvanex is already authorised in the European Union (EU) to protect against smallpox, mpox and the disease caused by the vaccinia virus in adults. It contains a live, highly weakened form of a virus called "modified vaccinia virus Ankara" (MVA-BN), which is related to the smallpox virus. EMA's human medicines committee (CHMP) based the recommendation to extend the use of Imvanex to adolescents on the <a href="https://www.clinicaltrials.gov/study/NCT05740982">interim results of a study</a> that compared the vaccine's ability to generate an immune response (produce virus-specific antibodies) in 315 adolescents and in 211 adults.
The immune response in adolescents was similar to adults. Therefore, it is inferred that the vaccine will provide similar protection in adolescents to that expected in adults. According to the submitted data, the safety profile of Imvanex in adolescents was comparable to that seen in adults and no additional risk has been identified. As part of its recommendation, EMA has requested the marketing authorisation holder to submit the final results of the study by 30 May 2025 to further characterise the information about safety in adolescents.
The Agency's assessment has important implications for the global response to the mpox outbreak in the Democratic Republic of the Congo (DRC) and other countries, which was <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern">declared a public health emergency of international concern (PHEIC)</a> by the World Health Organization (WHO) on 14 August 2024.
EMA is the regulatory agency of record for <a href="https://www.who.int/news/item/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox">prequalification of this vaccine by WHO</a> on 13 September 2024. This means that CHMP's assessment constitutes the basis for WHO prequalification approval to facilitate timely and increased access to this vaccine in communities with urgent need. Previously, EMA's assessment was also taken into account by the national regulatory authority of the DRC in the fast-track approval of the vaccine. In addition, WHO has cooperated in EMA's assessment of the extension of indication in adolescents, a population that is particularly vulnerable to mpox.
Mpox is a disease that is transmitted to people by animals, mainly rodents, but can also spread between people with direct contact. It is endemic in certain parts of Central and West Africa. The current surge in cases in the DRC and several neighbouring countries is driven by the mpox clade I strain that is known to cause a more severe form of mpox in humans than the mpox clade II strain that spread during the 2022/2023 PHEIC. Mpox can be fatal for people with weak immune systems.
Data indicate that Imvanex protects against both the clade I and clade II mpox strains.
In the EU, decisions on how vaccinations should be given are the prerogative of the expert bodies guiding vaccination campaigns in each Member State. The European Centre for Disease Prevention and Control (ECDC) <a href="https://www.ecdc.europa.eu/en/infectious-disease-topics/mpox/rapid-scientific-advice-public-health-measures-mpox-2024">published advice for public health authorities for mpox</a> on their website.

Biotech

News

Global

General

AEMD

APDN

CMRX

GOVX

MRNA

TNXP

VRAX

'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA

WIIM

APLT

Applied Therapeutics shares are trading higher after Leerink Partners and Citigroup raised their respective price targets on the stock.

Stifel analyst Jeffrey Stantial reiterates Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) with a Buy and lowers the price target from $259 to $223.

Price Target

Reiteration

Analyst Ratings

Stifel Reiterates Buy on Vail Resorts, Lowers Price Target to $223

Citigroup analyst Keith Horowitz maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Buy and raises the price target from $25 to $26.

Citigroup Maintains Buy on Regions Finl, Raises Price Target to $26

<a href="https://www.sec.gov/newsroom/press-releases/2024-140" title="https://www.sec.gov/newsroom/press-releases/2024-140">https://www.sec.gov/newsroom/press-releases/2024-140</a>

Legal

MQBKY

"SEC Charges Advisory Firm Macquarie Investment Management Business Trust with Fraud; Firm To Pay Nearly $80 Million In Connection With Overvaluing Assets And Engaging In Unlawful Cross Trades" - SEC

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Neutral.

ACET

HC Wainwright & Co. Reiterates Neutral on Adicet Bio

FANH

Fanhua shares are trading lower. The company reported H1 financial results.

Intelligent Bio Solutions Inc. - Common Stock

INBS

Intelligent Bio Solutions shares are trading lower. The company reported Q4 financial results.

MoneyHero shares are trading lower. The company reported Q2 financial results.

Citigroup analyst Jason Bazinet maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $110 to $155.

Citigroup Maintains Buy on AppLovin, Raises Price Target to $155

Macquarie analyst Tim Nollen maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Neutral and lowers the price target from $94 to $91.

Macquarie Maintains Neutral on Walt Disney, Lowers Price Target to $91

ELWS

Earlyworks shares are trading higher after the company announced a business alliance agreement with CIACA DIGITAL to support the expansion of Web3 businesses.

Stifel analyst Simon Yarmak maintains SITE Centers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) with a Buy and raises the price target from $65 to $65.25.

SITC

Stifel Maintains Buy on SITE Centers, Raises Price Target to $65.25

Citigroup analyst Keith Horowitz maintains Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) with a Neutral and raises the price target from $65 to $70.

Citigroup Maintains Neutral on Bank of New York Mellon, Raises Price Target to $70

KSPI

Joint Stock Company Kaspi.Kz shares are trading lower after Culper Research issued a report on the company.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) with a Buy and maintains $5 price target.

ONCY

HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target

Citigroup analyst Thomas Palmer maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Neutral and lowers the price target from $76 to $75.

Citigroup Maintains Neutral on General Mills, Lowers Price Target to $75

Home Depot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) has agreed to a nearly $2 million settlement to address allegations from California prosecutors that the company overcharged customers at checkout due <a href="https://www.benzinga.com/markets/equities/24/09/40915432/home-depot-agrees-to-2m-settlement-in-customer-overcharging-lawsuit">to price discrepancies.</a>
Meanwhile, overbought stocks nearing resistance levels often experience reversals, and Home Depot&#8217;s stock is currently showing these signs. With its share price approaching a key resistance point, it stands out as our Stock of the Day.
Most of the time, a stock stays within its usual or typical trading range. But sometimes, investors and traders can be aggressive and emotional. Their buying can push the stock above this range, which is considered overbought.
This is an important dynamic. It will draw sellers into the market. They will be expecting a reversion to the mean or move lower. Their selling could put pressure on the stock and force it down.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40938732/wall-street-ramps-up-interest-rate-cut-bets-after-fed-meeting-the-hard-landing-crow">Wall Street Ramps Up Interest Rate Cut Bets After Fed Meeting: &#8216;The Hard-Landing Crowd Should Disperse,&#8217; Economist Says</a>
The bottom half of the chart below shows the Relative Strength Index (RSI), a popular momentum indicator. When the blue line crosses above the horizontal red line, it indicates overbought conditions, which is now the case.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="632" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19112247/hd-chart-1024x632.png" alt="" class="wp-image-556556" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19112247/hd-chart-1024x632.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19112247/hd-chart-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19112247/hd-chart-768x474.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19112247/hd-chart.png 1177w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The reason resistance often forms at previous levels is rooted in investor psychology, specifically buyer&#8217;s remorse.
There are traders and investors who bought Home Depot when it was at a peak of around $395 in March and came to regret their decision when the stock sold off just after. Some of them vowed to sell their shares if they could get out of the position without losing any money.
As a result, if the stock gets back to their buying price, they will be placing sell orders. And if there are enough of these orders, it will create resistance at the level once again.
Stocks can pull back from resistance due to anxious sellers who fear that others might be willing to sell at a lower price. They understand that buyers will likely turn to those sellers, driving prices down.
So, they reduce the prices at which they are willing to sell. Other anxious sellers see this and do the same thing, resulting in a snowball effect that forces the shares into a downtrend.
The best traders understand psychology. They recognize that resistance often forms at previous peaks due to buyer&#8217;s remorse and that stocks typically pull back from resistance as anxious sellers emerge. This insight enables them to capitalize on these movements and profit.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40941053/s-p-500-dow-jones-hit-record-highs-magnificent-7-add-400-billion-after-feds-histori">S&amp;P 500, Dow Jones Hit Record Highs: Magnificent 7 Add $400 Billion After Fed&#8217;s Historic Interest Rate Cut</a></li>
</ul>
Photo: Shutterstock

Technicals

Trading Ideas

Stock Of The Day: Home Depot Agrees To Settlement, While Overbought Signals Warn Of Potential Sell-Off

Associated Capital Group Shares Resumed Trade

Citigroup analyst Yigal Nochomovitz maintains Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) with a Buy and raises the price target from $8 to $11.

Citigroup Maintains Buy on Applied Therapeutics, Raises Price Target to $11

Parkit Enterprise (TSE:PKT) has released an update. Parkit Enterprise Inc. has announced a significant rise in its fiscal year 2023 revenue and net...

Parkit Enterprise Reports Strong 2023 Growth

Parkit Enterprise FFO of C$0.01

In a report released today, Himanshu Gupta CFA from Scotiabank maintained a Hold rating on Parkit Enterprise (PKTEF – Research Report), with a pric...

Scotiabank Keeps Their Hold Rating on Parkit Enterprise (PKTEF)

Parkit Enterprise (TSE:PKT) has released an update. Parkit Enterprise Inc. has successfully finalized the purchase of an industrial property in Win...

Parkit Enterprise Expands Winnipeg Portfolio

Parkit Enterprise (TSE:PKT) has released an update. Parkit Enterprise Inc. showcased a robust financial performance in Q1 2024, reporting a substan...

Parkit Enterprise Posts Strong Q1 Growth

Parkit Enterprise reports Q1 results

Scotiabank Sticks to Their Hold Rating for Parkit Enterprise (PKTEF)

Parkit Enterprise (TSE:PKT) has released an update. Parkit Enterprise Inc. has announced a strong second quarter in 2024, with a notable 16% increa...

Parkit Enterprise Reports Robust Q2 2024 Growth

Parkit Enterprise reports Q2 results

Scotiabank analyst Himanshu Gupta CFA maintained a Hold rating on Parkit Enterprise (PKTEF – Research Report) today and set a price target of C$0.6...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

(PKTEF) Forecast

(PKTEF) Stock, Quote.Headers.trade-ideas